- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05803811
결장 전달 비타민 B2가 건강한 노인의 장내 미생물 및 관련 건강 바이오마커에 미치는 영향
The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Cork, 아일랜드
- Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
- Between 50 and 70 years of age.
- Has a BMI of between 18.5 - 30 Kg/m2.
- Participants have had a stable body weight (≤5 % change) over the past 3-months.
- Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
- Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
- Maintain current level of physical activity.
- Willing to consume the investigational product daily for the duration of the study.
- Female participants in menopause for at least the last one year. -
Exclusion Criteria:
-
Are hypersensitive to any of the components of the test product.
-
Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)
-
Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.
-
Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).
-
Is a smoker or vaper.
-
Vegetarian or vegan.
-
Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).
-
Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
-
Has a currently active eating disorder.
-
Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.
-
Is having a typical fibre intake >30 g fibre/day.
-
Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.
-
If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.
-
Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.
-
Has a current or history of any gastrointestinal cancer
-
Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).
-
Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).
-
Have a current malignant disease or any concomitant end-stage organ disease.
-
Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
-
Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
-
Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.
-
If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).
-
Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).
-
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low dose
Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
실험적: Mid dose
Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
실험적: high dose
Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
위약 비교기: Placebo
One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Faecal microbial composition
기간: from baseline to 12 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12 |
from baseline to 12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Alpha diversity
기간: from baseline to 12 weeks
|
Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12. |
from baseline to 12 weeks
|
|
Beta diversity
기간: week 0 to week 12
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12 |
week 0 to week 12
|
|
Faecal microbial metabolites fatty acid content at baseline and week 12
기간: from baseline to 12 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12 |
from baseline to 12 weeks
|
|
Acetate, Propionate and Butyrate
기간: baseline and week 12
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12. |
baseline and week 12
|
|
Intestinal inflammation
기간: from baseline to 12 weeks
|
Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12 |
from baseline to 12 weeks
|
|
Intestinal barrier integrity
기간: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Oxidative stress in blood
기간: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Inflammatory status in blood
기간: from baseline to 12 weeks
|
Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12. |
from baseline to 12 weeks
|
|
Gastrointestinal symptoms
기간: from baseline to 12 weeks
|
Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12. |
from baseline to 12 weeks
|
|
health-related quality of life
기간: from baseline to 12 weeks
|
Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase. |
from baseline to 12 weeks
|
|
Stool consistency
기간: from baseline to 12 weeks
|
Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively. |
from baseline to 12 weeks
|
|
Stool frequency
기간: from baseline to 12 weeks
|
Stool frequency, as reported in the daily eDiary app (at baseline and week 12). |
from baseline to 12 weeks
|
|
Systemic vitamin status
기간: from baseline to 12 weeks
|
The concentration of B vitamins in blood at baseline |
from baseline to 12 weeks
|
|
Faecal physiological pH and redox
기간: from baseline to 12 weeks
|
Faecal physiological parameters measured as pH and redox potential at baseline and at week 12. |
from baseline to 12 weeks
|
|
Faecal microbial composition at week 4
기간: from baseline to 4 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4. |
from baseline to 4 weeks
|
|
Alpha diversity at week 4
기간: baseline to Week 4.
|
Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4. |
baseline to Week 4.
|
|
Beta diversity at week 4
기간: week 0 to week 4
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4 |
week 0 to week 4
|
|
Microbial metabolites at week 4
기간: from baseline to 4 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4. |
from baseline to 4 weeks
|
|
Acetate, Propionate and Butyrate at week 4
기간: week 0 to week 4
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4. |
week 0 to week 4
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Skin barrier integrity
기간: from baseline to 12 weeks
|
Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12. |
from baseline to 12 weeks
|
|
Skin hydration
기간: from baseline to 12 weeks
|
Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12. |
from baseline to 12 weeks
|
|
Objective skin-health
기간: from baseline to 12 weeks
|
Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12. |
from baseline to 12 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Prof Timothy Dinan, Cork University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2020-11-11-VITB2
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .